1 min readResearch Affirms Imaging Technique’s Ability to Characterize Healthy and Non-Healthy Tissue
Bellingham, WA and Cardiff, UK — In an article published in the peer-reviewed SPIE publication Journal of Biomedical Optics (JBO), “Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens,” research observed across 92 ex vivo breast specimens suggests that there is little to no impact on the optical signatures of breast tissue after neoadjuvant chemotherapy.
The results of the study, in which diffuse reflectance spectroscopy (DRS) measurements were performed on 92 ex vivo breast specimens from 92 patients treated with and without neoadjuvant chemotherapy, show that contrast between healthy tissue and tumour tissue is not altered due to neoadjuvant chemotherapy, suggesting that the same reflectance spectral signatures can be used for tumour margin guidance independent of the chemotherapy status of the patient.
Because healthy and tumour tissue can be readily discriminated, tumour-margin assessment by DRS — which can discriminate different tissue types based on optical characteristics — becomes a feasible consideration during breast-conserving surgery, even if the patient has received neoadjuvant chemotherapy prior to surgery, a procedure that has become commonplace. The ultimate goal of the intra-surgery application of DRS would allow the surgeon to assess the tissue while performing the resection of tumours to ensure that the resection margin is clear of tumour tissue.
According to JBO Editor-in-Chief, SPIE Fellow, and MacLean Professor of Engineering at the Thayer School of Engineering at Dartmouth College, New Hampshire, Brian W. Pogue, the paper and its findings are notable due to the large number of clinical samples analyzed, and the consequent relevance to assessing neoadjuvant chemotherapy changes. “While a significant amount of work has been done defining the spectral signatures of breast cancer tumours and showing that this can be used for guidance, this is one of the first attempts to examine tumours following neoadjuvant chemotherapy as well. The results show that the signatures do not appear to change and so the status of the patient would not confound spectral imaging to help define the lumpectomy margin.”
Article adapted from a SPIE (International society for optics and photonics) news release.
Publication: Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens. de Boer, LL et al. Journal of Biomedical Optics (November 26, 2019): Click here to view.